Trials
2 active
6 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.”In the company’s words, NCT07363720 on ClinicalTrials.gov
- Other names
- TAK-861
Other drugs for Narcolepsy Type 1 (NT1)
- ALKS 2680Alkermes, Inc. · Phase 3
- CleminorextonCentessa Pharmaceuticals (UK) Limited · Phase 2/3
- PitolisantHarmony Biosciences · Phase 3
- SamelisantSuven Life Sciences Limited · Phase 3
- XywavJazz Pharmaceuticals · Phase 3
- E2086Eisai · Phase 2
Coming up2
- 17 DecPhase 3 trial completes · ClinicalTrials.gov
- 28 Feb 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 17 Dec 2026 | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | |
| Phase 2/3Recruiting | 28 Feb 2028 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | |
| Phase 3Completed | 3 Jun 2025 | A Study of TAK-861 for the Treatment of Narcolepsy Type 1 | |
| Phase 3Completed | 4 Jun 2025 | A Study of TAK-861 in People With Narcolepsy Type 1 | |
| Phase 2Completed | 13 Dec 2023 | A Study of TAK-861 in Participants With Narcolepsy Type 2 | |
| Phase 2Completed | 14 Dec 2023 | A Study of TAK-861 in Participants With Narcolepsy Type 1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026